{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:18:14Z","timestamp":1793413094656,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00417-026-07253-w","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:29:09Z","timestamp":1777264149000},"page":"2589-2599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral therapeutic interventions for central serous chorioretinopathy: A systematic review"],"prefix":"10.1007","volume":"264","author":[{"given":"Ferdiriva","family":"Hamzah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Azrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supanji","family":"Supanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitalisa Andayani","family":"Adriono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Shinojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"7253_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1442-9071.2012.02848.x","volume":"41","author":"G Liew","year":"2013","unstructured":"Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201\u2013214. https:\/\/doi.org\/10.1111\/j.1442-9071.2012.02848.x","journal-title":"Clin Exp Ophthalmol"},{"key":"7253_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82\u2013118. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"7253_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ph13100264","volume":"13","author":"M Nicol\u00f2","year":"2020","unstructured":"Nicol\u00f2 M, Ferro Desideri LF, Vagge A, Traverso CE (2020) Current pharmacological treatment options for central serous chorioretinopathy: a review. Pharmaceuticals 13:264. https:\/\/doi.org\/10.3390\/ph13100264","journal-title":"Pharmaceuticals"},{"key":"7253_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40123-024-00952-9","volume":"13","author":"MJ Sirks","year":"2024","unstructured":"Sirks MJ, Subhi Y, Rosenberg N et al (2024) Perspectives and update on the global shortage of verteporfin (Visudyne\u00ae). Ophthalmol Ther 13:1821\u20131831. https:\/\/doi.org\/10.1007\/s40123-024-00952-9","journal-title":"Ophthalmol Ther"},{"key":"7253_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41433-019-0568-y","volume":"34","author":"W Fusi-Rubiano","year":"2020","unstructured":"Fusi-Rubiano W, Saedon H, Patel V, Yang YC (2020) Oral medications for central serous chorioretinopathy: a literature review. Eye 34:809\u2013824. https:\/\/doi.org\/10.1038\/s41433-019-0568-y","journal-title":"Eye"},{"key":"7253_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-022-00385-1","volume":"8","author":"CQ Felipe","year":"2022","unstructured":"Felipe CQ, Biancardi AL, Civile VT, Carvas Junior N, Serracarbassa PD, Koike MK (2022) Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retin Vitr 8:1\u201319. https:\/\/doi.org\/10.1186\/s40942-022-00385-1","journal-title":"Int J Retin Vitr"},{"key":"7253_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13080170","volume":"13","author":"R Venkatesh","year":"2020","unstructured":"Venkatesh R, Pereira A, Jayadev C et al (2020) Oral eplerenone versus observation in the management of acute central serous chorioretinopathy: a prospective, randomized comparative study. Pharmaceuticals 13:1\u201311. https:\/\/doi.org\/10.3390\/ph13080170","journal-title":"Pharmaceuticals"},{"key":"7253_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/joco.joco_13_22","volume":"36","author":"M Akhlaghi","year":"2024","unstructured":"Akhlaghi M, Dehghani A, Kianersi F, Khalili MR, Tohidi M, Jahanbani-Ardakani H (2024) Effect of eplerenone treatment in patients with central serous retinopathy: a double-blind randomized clinical trial. J Curr Ophthalmol 36:61\u201365. https:\/\/doi.org\/10.4103\/joco.joco_13_22","journal-title":"J Curr Ophthalmol"},{"key":"7253_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13110336","volume":"13","author":"LC Chen","year":"2020","unstructured":"Chen LC, Ma JW, Shieh PC, Horng CT (2020) Oral treatment of central serous chorioretinopathy patients using propranolol tablets. Pharmaceuticals 13:1\u201314. https:\/\/doi.org\/10.3390\/ph13110336","journal-title":"Pharmaceuticals"},{"key":"7253_CR10","first-page":"99","volume":"17","author":"MB Rahbani-Nobar","year":"2011","unstructured":"Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 17:99\u2013103","journal-title":"Mol Vis"},{"key":"7253_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/TCRM.S50407","volume":"9","author":"Y Dang","year":"2013","unstructured":"Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y (2013) The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. Ther Clin Risk Manag 9:355\u2013360. https:\/\/doi.org\/10.2147\/TCRM.S50407","journal-title":"Ther Clin Risk Manag"},{"key":"7253_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(19)32981-2","journal-title":"Lancet"},{"key":"7253_CR13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00417-016-3315-0","volume":"254","author":"O Zavoloka","year":"2016","unstructured":"Zavoloka O, Bezditko P, Lahorzhevska I, Zubkova D, Ilyina Y (2016) Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:1737\u20131742. https:\/\/doi.org\/10.1007\/s00417-016-3315-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7253_CR14","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet E, Beydoun T, Rothschild PR et al (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505\u20132515. https:\/\/doi.org\/10.1097\/IAE.0000000000000614","journal-title":"Retina"},{"key":"7253_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","volume":"102","author":"X Sun","year":"2018","unstructured":"Sun X, Shuai Y, Fang W et al (2018) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol 102:1060\u20131065. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311096","journal-title":"Br J Ophthalmol"},{"key":"7253_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","volume":"37","author":"F Pichi","year":"2017","unstructured":"Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P (2017) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37:1115\u20131125. https:\/\/doi.org\/10.1007\/s10792-016-0377-2","journal-title":"Int Ophthalmol"},{"key":"7253_CR17","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1111\/aos.13491","volume":"95","author":"R Schwartz","year":"2017","unstructured":"Schwartz R, Habot-Wilner Z, Martinez MR et al (2017) Eplerenone for chronic central serous chorioretinopathy: a randomized controlled prospective study. Acta Ophthalmol 95:e610\u2013e618. https:\/\/doi.org\/10.1111\/aos.13491","journal-title":"Acta Ophthalmol"},{"key":"7253_CR18","doi-asserted-by":"publisher","first-page":"NC01","DOI":"10.7860\/JCDR\/2024\/68431.19108","volume":"18","author":"AD Sarkar","year":"2024","unstructured":"Sarkar AD, Thakur SKD, Biswas S, Sarkar AD, Sarkar S (2024) Efficacy and safety of oral eplerenone in acute central serous chorioretinopathy: a randomised controlled study. J Clin Diagn Res 18:NC01\u2013NC04. https:\/\/doi.org\/10.7860\/JCDR\/2024\/68431.19108","journal-title":"J Clin Diagn Res"},{"key":"7253_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5507\/bp.2013.015","volume":"159","author":"O Chrapek","year":"2015","unstructured":"Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M (2015) Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap 159:120\u2013123. https:\/\/doi.org\/10.5507\/bp.2013.015","journal-title":"Biomed Pap"},{"key":"7253_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","volume":"38","author":"E Rahimy","year":"2018","unstructured":"Rahimy E, Pitcher JD 3rd, Hsu J, Adam MK, Shahlaee A, Samara WA et al (2018) A randomized double-blind placebo-controlled pilot study of eplerenone for the treatment of central serous chorioretinopathy (Ecselsior). Retina 38:962\u2013969. https:\/\/doi.org\/10.1097\/IAE.0000000000001649","journal-title":"Retina"},{"key":"7253_CR21","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41433-025-03894-z","volume":"39","author":"YJ Kim","year":"2025","unstructured":"Kim YJ, Sivaprasad S, Aslam T, Mekjavi\u0107 PJ, Bal\u010di\u016bnien\u0117 VJ, Visser L et al (2025) Treatment of central serous chorioretinopathy: new options an old disease. Eye 39:2375\u20132388. https:\/\/doi.org\/10.1038\/s41433-025-03894-z","journal-title":"Eye"},{"key":"7253_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ceo.14201","volume":"51","author":"AT Fung","year":"2022","unstructured":"Fung AT, Yang Y, Kam AW (2022) Central serous chorioretinopathy: a review. Clin Exp Ophthalmol 51:243\u2013270. https:\/\/doi.org\/10.1111\/ceo.14201","journal-title":"Clin Exp Ophthalmol"},{"key":"7253_CR23","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s40123-023-00816-8","volume":"12","author":"P Viggiano","year":"2023","unstructured":"Viggiano P, Boscia G, Borrelli E et al (2023) Choriocapillaris reperfusion in resolved chronic central serous chorioretinopathy treated with eplerenone: long-term effects on the fellow eye. Ophthalmol Ther 12:3199\u20133210. https:\/\/doi.org\/10.1007\/s40123-023-00816-8","journal-title":"Ophthalmol Ther"},{"key":"7253_CR24","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/bcp.15213","volume":"88","author":"E Abdelhakeem","year":"2022","unstructured":"Abdelhakeem E, El-Nabarawi M, Shamma R (2022) Eplerenone repurposing in management of chorioretinopathy: mechanism, nanomedicine-based delivery applications and future trends. Br J Clin Pharmacol 88:2665\u20132672. https:\/\/doi.org\/10.1111\/bcp.15213","journal-title":"Br J Clin Pharmacol"},{"key":"7253_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40123-018-0121-2","volume":"7","author":"I Zucchiatti","year":"2018","unstructured":"Zucchiatti I, Sacconi R, Parravano MC et al (2018) Eplerenone versus observation in the treatment of acute central serous chorioretinopathy: a retrospective controlled study. Ophthalmol Ther 7:109\u2013118. https:\/\/doi.org\/10.1007\/s40123-018-0121-2","journal-title":"Ophthalmol Ther"},{"key":"7253_CR26","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.2147\/OPTH.S151933","volume":"6","author":"NA Dhirani","year":"2017","unstructured":"Dhirani NA, Yang Y, Somani S (2017) Long-term outcomes in half-dose verteporfin photodynamic therpy for chronic central serous retinopathy. Clin Ophthalmol 6:11:2145\u20132149. https:\/\/doi.org\/10.2147\/OPTH.S151933","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"7253_CR27","doi-asserted-by":"publisher","first-page":"e0181479","DOI":"10.1371\/journal.pone.0181479","volume":"12","author":"F Haga","year":"2017","unstructured":"Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a3-year follow-up study. PLoS ONE 12(7):e0181479. https:\/\/doi.org\/10.1371\/journal.pone.0181479","journal-title":"PLoS ONE"},{"key":"7253_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/IAE.0000000000001913","volume":"39","author":"JH Lee","year":"2019","unstructured":"Lee JH, Lee SC, Kim H, Lee CS (2019) Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy. Retina 39:127\u2013133. https:\/\/doi.org\/10.1097\/IAE.0000000000001913","journal-title":"Retina"},{"key":"7253_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.oret.2018.09.003","volume":"3","author":"SK Wang","year":"2019","unstructured":"Wang SK, Sun P, Tandias RM, Seto BK, Arroyo JG (2019) Mineralocorticoid receptor antagonists in central serous chorioretinopathy: a meta-analysis of randomized controlled trials. Ophthalmol Retin 3:154\u2013160. https:\/\/doi.org\/10.1016\/j.oret.2018.09.003","journal-title":"Ophthalmol Retin"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07253-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:53:41Z","timestamp":1789455221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07253-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7253"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07253-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, the keyword \"Randomized controlled trials\" was mistakenly misspelled as \"Andomized controlled trials.\" The error has been corrected to ensure accuracy and clarity.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human ethics and consent to participate declarations:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}